"Shotgun approach" to functional claiming fatal to RNA editing claims in Australia By Dr Claire Gregg on Wednesday, November 18, 2026 #patents Australia biotech Claire Gregg clarity gene editing insufficiency OzKat +
Australian Federal Court finds biosimilar etanercept manufacturing processes do not infringe Pfizer's ENBREL process patent By Dr Claire Gregg on Monday, November 09, 2026 #patents biotech claim construction Claire Gregg OzKat pharmaceutical patents +
Patent Litigation Europe 2027 with IPKat readers’ discount and new speakers announced By Eleonora Rosati on Tuesday, October 27, 2026 biotech events IPKat readers litigation Patent Litigation Europe 2027 patents pharma +
Pharma & Biotech Patent Litigation Summit (& UPC Litigation Forum) returns to Amsterdam in January with 15% IPKat readers’ discount By Eleonora Rosati on Tuesday, November 26, 2024 biotech events IPKat readers patents pharma upc +
Pharma and Biotech Patent Litigation Summit returns to Amsterdam with IPKat readers’ discount By Eleonora Rosati on Tuesday, October 10, 2023 biotech events IPKat readers life sciences patents pharma +
Is it time to rethink the patent drawing requirements? By Dr Rose Hughes on Friday, January 25, 2019 biotech biotech patents epo insufficiency methods of treatment mouse data patents PCT drawing requirements plausibility Rule 11 PCT Rule 46 EPC +
No deal Brexit - what will happen to patents - particularly SPCs and the UPC? By Rosie Burbidge on Tuesday, September 25, 2018 biotech Brexit Brexit patents compulsory licences EU european union patents SPC Unified Patent Court unitary patent upc +